🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

19 recruiting trials

for Recurrent or Metastatic Nasopharyngeal Carcinoma

Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC NCT06657690Phase 21 site📍 Zhuhai Sun Yat-sen University · Tests: Irinotecan liposome, S-1 A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma NCT06976190Phase 31 site📍 Guangzhou Lepu Biopharma Co., Ltd. · Tests: MRG003 + Pucotenlimab, Gemcitabine, Docetaxel, or Capecitabine TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer NCT06868433Phase 12 sites📍 Atlanta📍 Atlanta Emory University · Tests: Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography, Echocardiography, Magnetic Res… Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC NCT06197776n/a1 site📍 Guangzhou Sun Yat-sen University · Tests: cisplatin-based chemoradiotherapy combined with immunotherapy A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) NCT06241599Phase 2, Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: GP/PFLL+AK104, GP/PFLL+placebo Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: Becotatug Vedotin Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors NCT07625423Phase 11 site📍 Chengdu West China Hospital · Tests: EDS01 1.0×10^11 VP + Toripalimab, EDS01 5.0×10^11 VP + Toripalimab, EDS01 1.0×10^12 VP + Toripalimab Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" NCT01365169NA1 site📍 Houston M.D. Anderson Cancer Center · Tests: Exercise Intervention, Health Telemonitoring, Health Telemonitoring, Health Telemonitoring, Health Telemonitoring Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC NCT06472713Phase 21 site📍 Zhuhai Ming-Yuan Chen · Tests: Mitoxantrone hydrochloride liposome injection, PD-1 Inhibitors Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial NCT07070479Phase 26 sites📍 Guangzhou📍 Guangzhou📍 Guangzhou Ming-Yuan Chen · Tests: Ivonescimab, Nimotuzumab, Irinotecan liposome, S-1, Mitoxantrone Hydrochloride Liposome Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer NCT06029270Phase 295 sites📍 Dublin📍 Fremont📍 Fresno National Cancer Institute (NCI) · Tests: Biospecimen Collection, Bone Scan, Carboplatin, Cisplatin, Computed Tomography A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors NCT06437522Phase 21 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, PD-1 monoclonal antibody Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation NCT06662058NA1 site📍 Atlanta Emory University · Tests: Audiometric Test, Audiometric Test, Audiometric Test, Interview A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy NCT06839066Phase 215 sites📍 Fuzhou📍 Dongguan📍 Guangzhou Shanghai Henlius Biotech · Tests: HLX43 DOSE 1, HLX43 DOSE 2, HLX43 DOSE 3 A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. NCT07258979Phase 1, Phase 220 sites📍 Chongqing📍 Fuzhou📍 Xiamen MediLink Therapeutics (Suzhou) Co., Ltd. · Tests: YL201, Toripalimab, Cisplatin Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial NCT07101744Phase 21 site📍 Guangdong Sun Yat-sen University · Tests: Iparomlimab and Tuvonralimab Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial NCT06636734Phase 22 sites📍 Atlanta📍 Atlanta Emory University · Tests: Biospecimen Collection, Computed Tomography, Lovastatin, Magnetic Resonance Imaging, Pembrolizumab Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma NCT07581821Phase 21 site📍 Zhuhai Ming-Yuan Chen · Tests: Sintilimab + Anlotinib + taxane-based chemotherapy Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC NCT06177301Phase 31 site📍 Shanghai Fudan University · Tests: Tislelizumab combined with GX, Tislelizumab combined with GP
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy